Clinical Trial

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Study acronym: FIL_RICCO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prospective, multicenter, single arm, phase II study, to evaluate the efficacy of the combination rituximab-golcadomide as a chemo free approach in a population of older patients with new diagnosis of DLBCL, defined as frail according to a sGA evaluation and not candidate for the standard R-CHOP (or R-CHOP like) treatments.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-17; most recent amendment 2025-12-31.
Status change: Not Yet Recruiting → Recruiting 2025-08-07
Trial Details
NCT Number NCT06835530
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Diffuse Large B Cell Non-Hodgkin Lymphoma
Enrollment 47 participants
Start Date 2025-04-09
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-02